Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .